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INTRODUCTION 
 
Milk is a unique, nutrient-dense, food. Key to early development of mammals, milk 
constitutes a major source of energy, high-quality protein, and vitamins and minerals such 
as vitamin D, calcium, and potassium (Smilowitz et al., 2005; Gaucheron, 2005). Beyond 
its key role in neonatal nutrition, milk and milk-derived products are also major sources of 
nutrients for adults. The ability of humans to carry on drinking milk through adulthood has 
developed gradually over the past eight millennia, in association with agriculture and 
dairying (Curry., 2013), and it is due to the persistence of the enzyme lactase past early 
childhood. The rise of distinct genetic mutations for lactase persistence developed in at 
least four different geographic regions on the planet (i.e., lactase hotspots), and, arguably, 
provided a major selective advantage (Bersaglieri, et al., 2004). Today, one-third of 
humans produce lactase during adulthood, with prevalence being greater in places like 
northern Europe, where over 90% of people can drink milk, but also in West Africa, the 
middle east, and  south Asia (Curry., 2013; Liebert et al., 2017).   
 
Despite the arguably obvious benefits that milk can provide to human populations 
as a source of nutrients, its place as a component of a healthy diet has been questioned. 
Indeed, over the past five decades, changes in consumer perception, dietary guidelines, 
public health messages, and policy, have all resulted in a shift in the patterns of 
consumption of milk and dairy products, particularly those of higher fat content. The start 
of these changes can be traced to the emergence of the “diet-heart hypothesis” in the 
1950’s. Based on limited epidemiological data, its fundamental premise was that fat 
consumption could cause cardiovascular disease (CVD) in humans. In spite of being 
criticized as “invalid” and being based on a “tenuous association” from the onset 
(Yerushalmy and Hilleboe, 1957), the diet-heart hypothesis became a central piece of 
dietary advice in the following decades, in particular, to reduce CVD risk. A generalized 
“fear of fats” has spread since then and shaped consumer’s choices, who nowadays tend 
to look for reduced-fat foods as healthier alternatives to full-fat options, in hopes of 
reducing intake of fat and ‘calories’, and the risk of heart problems and obesity. 
Simultaneously, milk avoidance has become more prevalent (Figure 1), and new 
beverages of plant origin with low contents of saturated fats have become available, 
replacing cow’s milk in the diet (e.g., the so –called soy and almond milks). In contrast to 
current perceptions and dietary advice, an important body of literature has emerged over 
the past decade that challenges the contemporary views associating saturated animal fat 
consumption to human disease. Such studies suggest that dairy in general, as well as 
full-fat dairy, may decrease the risk for CVD. Furthermore, recent studies suggest that full 
fat dairy may actually protect from obesity and associated chronic diseases. This review 
 will summarize available evidence from recent meta-analyses, and observational and 
randomized controlled trials (RCTs), on the effects of dairy consumption on human 
health. The public health role of dairy products in relation to their potential to prevent or 
ameliorate the onset of chronic diseases will be discussed.  
 
FAT CONSUMPTION AND HUMAN DISEASE 
 
The Diet-heart Hypothesis - Background and Classic Studies 
 
The now prevailing concept that saturated fats of animal origin are detrimental to 
human health can be traced to some suggestive pieces of evidence originated in the 20th 
century. First, the ground-breaking studies of Ignatowski in 1908 and Anichkov in 1913 
demonstrated the ability of animal fats and, specifically, cholesterol, to cause 
atherosclerotic lesions, raise plasma cholesterol, and cause death in rabbit models of 
atherosclerosis (Konstantinov et al., 2006). Second, during the 1950’s, Ancel Keys 
produced epidemiological data that seemed to identify dietary fat as a major cause of 
heart disease. In two commonly known studies, Keys and collaborators showed some 
seemingly strong associations between national death rates for middle-aged men from 
arteriosclerotic and degenerative heart disease and the proportion of fat-calories available 
in their national diets (Keys, 1953; Keys et al., 1966). His data relating availability of 
energy from fat and cardiovascular-related death led him to conclude that “dietary fat 
somehow is associated with cardiac disease mortality, at least in middle age”. These 
studies propelled the extensively known diet-heart hypothesis that related dietary factors 
to the incidence of cardiovascular disorders. The validity of this hypothesis was quickly 
challenged by Yerushalmy and Hilleboe (1957), and its acceptance has remained far from 
unanimous ever since it was first proposed. In their methodological note, the authors 
attempted to evaluate whether the proposed hypothesis could actually reflect “known or 
ascertainable facts” which may allow for the generalization of this premise. The authors 
pointed at several limitations, including 1) small sample size (i.e., only 6 countries were 
used in Key’s original study); 2) the possible effects of unaccounted confounders (e.g., 
underreporting in countries with lower economic status who cannot afford meat and 
dairy); 3) the fact that no actual data on fat consumption was used (i.e., availability was 
used); 4) the lack of specificity of the relationship (i.e., protein consumption also related 
to death); 5) variation in deaths from cardiac disease are largely variable across countries 
at any given fat availability category. Some interesting points emerging from their 
methodological analysis include: first, the strength of the association is greatly reduced 
when more countries are included (n= 22); second, the relationship is not specific to fat; 
third, “almost no association” was found when correlating fat or protein with all causes of 
death. This last point merits attention because CVD is the leading cause of death in 
industrial countries, and consequently, the relationship in Keys’ studies would be 
expected to also hold for all-cause mortality. More recently, others (Willet, 2012) have 
pointed out that the countries chosen by Keys to represent low fat intake and low 
incidence of CVD were in fact less industrialized and showed differences in smoking 
habits, physical activity and obesity, thus complicating the generalization of the diet-heart 
hypothesis.  
 
 Dietary Lipids and CVD Risk  
 
The importance of cholesterol in the development of CVD in humans was first 
suggested by data extracted from the Framingham study, which enrolled 5127 men and 
women aged 30–59 years in Massachusetts, starting between 1948 and 1950. Following 
six years of longitudinal evaluation, cholesterol was identified as one of three risk factors 
for CVD (Kannel et al., 1961)1. Several other studies between the 1950’s and 1980’s 
found positive associations between serum (total) cholesterol and risk of CVD. With the 
advent of techniques to identify and measure circulating lipoproteins, it was further shown 
that cholesterol contained in very low-density lipoproteins (VLDL-C), as well as low-
density lipoproteins (LDL-C; i.e., ‘bad cholesterol’), correlates positively with CVD risk, 
while that found in high density lipoproteins (HDL-C; i.e., ‘good cholesterol), correlated 
negatively (see review by Parodi, 2009). In fact, LDL-C became the lead marker for 
atherogenicity and CVD risk, and thus, the main target and factor guiding CVD treatments 
in the last few decades (Stone et al., 2014). However, the role of LDL-C recently has been 
put into question as it is considered a very poor predictor of CVD (Sachdeva et al., 2009; 
Ravnskov et al., 2018). On the other hand, HDL-C (an indicator of cholesterol efflux) 
levels are used as a marker of reduced CVD risk (Rohatgi et al., 2014; Monette et al., 
2016), particularly when used as a ratio of total cholesterol to HDL-C (Castelli, 1988). In 
addition, increased triglyceride to HDL-C ratio is a more powerful predictor of coronary 
heart disease (Luz et al., 2008). 
 
While much of the focus has been historically placed on cholesterol, other factors 
seem to be important to predict CVD risk. Some of these include obesity, serum 
triglycerides, inactivity, hypertension, cigarette smoking and diabetes. Results from the 
Framingham cohort illustrate the importance of these cofactors, as, for example, 
accounting for glucose intolerance, high systolic blood pressure, smoking, and left 
ventricular hypertrophy increased CVD risk to 60.2, compared to only 3.9 when 
cholesterol alone was used (Kannel et al., 1979).   
 
Saturated Fats and Blood Lipids  
 
The ability of saturated fatty acids (SFA) to raise blood LDL-C is consistent across 
the literature, and it is well documented (Micha and Mozaffarian, 2008). Interest in this 
relationship stems from hypothesis that LDL particles may increase cholesterol 
accumulation in arterial walls, facilitating the formation of atheromatous plaque, and 
therefore increasing CVD risk (Kruth et al., 2001).  Consequently, efforts have been made 
to determine the atherogenic potential of individual SFA as a marker of CVD. For 
example, Ulbricht and Southgate (1991) proposed the atherogenic index, which is 
calculated by dividing the sum the SFA lauric (12:0), myristic (14:0) and palmitic (16:0), 
by the sum of omega 3 and 6, 18:1c9, and other monounsaturated fatty acids. Based on 
Hegsted’s work (1965), each factor is multiplied by an empirical constant according to its 
                                                      
1 Indeed, interest in cholesterol seemed justified, as atheromatous lesions are rich in free and esterified 
cholesterol, relative to normal arterial walls (Windaus, 1910). Moreover, cholesterol alone can cause 
atheromatous lesions in the vascular wall (Anitschkow and Chalatow, 1913).  
 
 capacity to raise or decrease cholesterol, using a value of 1 for all fatty acids and a value 
of 4 for 14:0. Because these presumably atherogenic fatty acids (12:0, 14:0, 16:0) 
represent 30-40% of cow’s milk triglycerides (Jensen, 2002; O'Donnell-Megaro et al., 
2011), some have concluded that dairy fat is a potential cholesterol-raising food, and, 
consequently, consumers have reduced the consumption of full-fat dairy (Wang and Li, 
2008). Simultaneously, official advice has focused on reducing the consumption of fat 
and saturated fat specifically. The dietary fat guidelines introduced in 1977 (US) and 1983 
(UK) (Harcombe et al., 2015) recommend to 1) reduce overall fat consumption to 30% of 
total energy intake and 2) reduce saturated fat consumption to 10% of total energy intake. 
It is important to note that, with these guidelines, the ability of SFA to raise blood HDL-C, 
and to reduce CVD risk, is implicitly ignored (Parodi, 2009). In fact, a meta-analysis of 60 
controlled trials showed that SFA have no effect on the ratio of total cholesterol to HDL-
C (lower is better) when SFA replace dietary carbohydrates (Mensink, et al., 2003). 
Furthermore, the allegedly “atherogenic” lauric acid reduces the ratio, mostly by 
increasing HDL-C. These observations challenge the notion that SFA are indeed 
atherogenic and that SFA sources like milk fat may have health-adverse effects.       
 
The disconnect between the expected effects of SFA-containing foods on CVD risk 
markers and the actual outcomes is well exemplified by the work of Lefevre et al., 2005. 
In this double-blind, randomized cross-over study, the authors report the effects of milk 
fat on health markers in males aged 22-64. Dietary supply of fat and SFA were adjusted 
by substituting low fat or non-fat dairy products for their higher fat equivalents. Energy 
from milk fat was progressively reduced to achieve fat and SFA energy consumption 
equivalent to an average American diet (AAD; 37% fat and 14% SFA; above current 
recommendations), and two diets with reduced fat and SFA content (Step I diet, 28% fat 
and 8.8% SFA; Step II diet, 24% fat and 6.2% SFA). The last two diets met current 
recommendations for energy intake from fat and SFA (Table 1). 
 
Table 1. Reductions in dairy fat consumption result in higher blood triglycerides and 
Total:HDL-Cholesterol (Lefevre et al., 2005) 
Effect of diets on lipid and lipoprotein concentrations1 
  
AAD 
14% SFA 
Step I diet  
8.8% SFA 
Step II diet 
6.2% SFA  
Total Cholesterol, mmol/L 4.82±0.69 4.59±0.62 4.39±0.662,3 
Triacylglycerol, mmol/L  1.06±0.65 1.20±0.762 1.22±0.802 
LDL Cholesterol, mmol/L 3.25±0.58 3.03±0.562 2.87±0.522,3 
HDL Cholesterol, mmol/L  1.07±0.23 0.99±0.222 0.95±0.222,3 
Apolipoprotein A-I, g/L 1.23±0.14 1.17±0.132 1.15±0.122,3 
Apolipoprotein B, g/L 0.97±0.19 0.93±0.202 0.9±0.182,3 
Total:HDL cholesterol 4.7±1.08 4.84±1.182 4.85±1.262 
1 All values are mean ± SD; n = 86. AAD, average American diet. 
2 Significantly different from AAD, P < 0.05 (ANOVA with Bonferroni corrections). 
3 Significantly different  from  Step  I  diet,  P  < 0.05  (ANOVA  with Bonferroni corrections). 
 
 As expected, the reduction of dairy SFA consumption resulted in reduced 
circulating LDL-C.  However, reductions of similar magnitude were observed for HDL-C. 
Furthermore, low fat diets increased circulating triglycerides and the ratio of total 
cholesterol to HDL-C (Total:HDL-C; i.e., the atherogenic ratio), both proxies for increased 
CVD risk. In this way, elevations observed by reducing dairy fat intake cast some 
concerns about the efficacy of low-fat diets to reduce CVD risk. Arguably, increased CVD 
risk may actually result from following this type of low-fat approach. Although factors like 
adiposity and insulin resistance of subjects may have influenced the responses to low-fat 
diets in this study, it is evident that the effects of such diets on the commonly used 
biomarkers (e.g., LDL-C, HDL-C, Total:HDL-C, and triglycerides) were certainly not what 
many may expect in terms of alleviation of CVD risk. Moreover, the validity of CVD 
biomarkers like LDL-C has dwindled recently, and the role of lipoproteins on CVD has 
shifted focus into their size (i.e., small and dense LDL profile is worse), number (i.e. 
Apolipoprotein B as a marker of atherogenic particles), and oxidation propensity, rather 
than their cholesterol content (Krauss, 2005; Parodi, 2009). An example comes from the 
guidelines of the American Heart Association, who, based on a recent review of available 
data, reported being unable to find evidence to support continued use of specific LDL–C 
and/or non-HDL–C treatment targets. In this way, the “bad cholesterol” is no longer the 
main factor guiding treatment (Stone et al., 2014).  
 
Even leaving CVD lipid biomarkers aside, under the diet-heart hypothesis, the 
effects of SFA on actual clinical outcomes should reflect harmful consequences on 
cardiovascular endpoints. Contrary to this expectation, a meta-analysis of prospective 
cohort studies that followed 347,747 subjects for 5 to 23 years found no association 
between saturated fat intake and CVD, both fatal and non-fatal (Siri-Tarino et al., 2010). 
Similarly, in a systematic review and meta-analysis of prospective cohort studies and 
RCTs (n = 78) with 649,812 participants, Chowdhury et al. (2014) reported no increase 
of relative risk of coronary outcomes associated with dietary or circulating SFA. Moreover, 
the authors reported an inverse association between circulating margaric acid (17:0, a 
marker of dairy fat intake) and coronary disease. Taken together, available evidence from 
prospective epidemiologic studies and RCT does not support guidelines encouraging 
reduced saturated fat consumption, particularly those from dairy. Whether this evidence 
can be considered sufficient to totally vindicate SFA and dairy, is still a matter for 
discussion; however, currently available data suggest the heavy focus on saturated fats 
may be not only unnecessary, but perhaps also detrimental. This is particularly true when 
considering that dairy fats may have been replaced with industrial trans fats of plant origin 
(e.g. margarines with high trans fat content), as well as refined sugars (i.e., fructose). 
Some trends exemplifying these dietary substitutions can be seen in Figure 1. Full fat milk 
has been partially substituted with lower-fat versions, while soft drinks consumption and 
fructose has risen in linearly. Importantly, there are cogent reasons to believe that the 
simultaneous reduction in consumption of some dairy products and the increase industrial 
trans fats and sugars could be detrimental. For example, non-ruminant (i.e., industrial) 
trans fats are nowadays recognized as harmful (Micha and Mozaffarian, 2008) and they 
relate strongly to heart disease and all-cause mortality (Oomen et al., 2001; de Souza et 
al., 2015). Similarly, a growing body of evidence indicates that most US adults currently 
consume excess added sugar (a source of fructose), and this is significantly associated 
 with obesity, metabolic syndrome, and CVD mortality (Johnson et al., 2009; Lustig et al., 
2010; Yang et al., 2014). In fact, the American Heart Association has recommended the 
reduction of dietary sugar intake by more than half (Johnson et al., 2009).  
 
 
 
Figure 1. (A) Trends of consumption of fluid milk as reduced-fat milks and whole milk from 
1975 to 2017 in the U.S. (B) Per capita availability (gallons/head/day) of 
carbonated soft drinks, 1947 - 2003 Source:  USDA, Economic Research 
Service. 2012; 2018. 
 
DAIRY CONSUMPTION AND HUMAN HEALTH OUTCOMES   
 
A Note on the Assessment of Evidence  
 
Evidence for claims related to lipid intake and human health come from a range of 
studies with varying degrees of causal strength, going from observational studies to 
controlled randomized clinical trials. Young and Karr (2011) give some perspective on the 
frequency at which observational claims fail to replicate, at an alarming rate of 80%. 
Further, in about 10% of the cases, when the claims from observational studies were 
tested in clinical trials they moved significantly in the opposite direction (Young and Karr; 
2011). These authors suggested that ‘‘any claim coming from an observational study is 
most likely to be wrong – wrong in the sense that it will not replicate if tested rigorously’’. 
Therefore, assessing the observational evidence that relates dietary intakes to common 
disease outcomes is, at the very least, problematic (Prentice, 2014). For instance, the 
validity of observational studies can be compromised by the necessary reliance placed 
on self-reported food intakes and can further be complicated by the effects of 
confounders, such as lifestyle factors that may impact the association. This highlights 
some of the problems with claims originated from ecological studies, such as the diet-
heart hypothesis, which now seems to lose validity in the face of stronger pieces of 
evidence, such as RCTs and prospective cohort studies, which contradict its original 
presuppositions (e.g., Micha and Mozaffarian, 2008; Ramsden et al., 2016). While 
bearing these limitations in mind, the interpretation of observational studies relating dairy 
intake and health outcomes can be in many instances a useful starting point for 
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 investigation and validation. Regardless, causation may only be derived from properly 
controlled experimentation.  
  
Obesity and Type 2 Diabetes 
 
One arguably important reason for the current trends of dairy fat avoidance (Figure 
1) is related to the interest in reducing excess energy intake. The common presumption 
is that dairy fat can be stored as body fat and thus contribute to weight gain, obesity, and 
cardiometabolic risk. This has driven dietary guidelines to recommend the consumption 
of low-fat dairy (Jensen et al., 2014). In contrast to guidelines and prevailing public 
sentiment, available evidence indicates dairy fat consumption is not related with the risk 
of weight gain. The comprehensive review of Kratz et al. (2013), which used a 
combination of observational and controlled studies, indicates that dairy fat consumption, 
both recorded or assessed via odd-chain fatty acid content in blood (e.g., 15:0 and 17:0), 
was inversely related with obesity risk. Similar findings were reported in a cross-sectional 
evaluation of full-fat milk consumption in three-year-old children (Beck et al., 2017). The 
multivariate analysis included potential demographic and nutritional confounders. The 
authors reported reduced odds for severe obesity in association with higher milk fat 
consumption, suggesting a protective effect of dairy fat against obesity in three-year-olds. 
Similarly, in a prospective cohort study of 18,438 healthy middle-aged women followed 
during 11 years and belonging to the Women’s Health Study, greater consumption of total 
dairy products reduced the risk of becoming overweight or obese. Furthermore, the lowest 
risk was observed at the highest quintile of high-fat dairy product intake (Rautiainen et 
al., 2016). Finally, in a meta-analysis of 29 RCTs, Chen et al. (2012) reported dairy 
consumption does not increase body weight gain or body fat gain. Moreover, dairy 
consumption results in modest beneficial effects on weight loss in short-term and energy-
restricted RCTs.     
 
Type 2 diabetes (T2D) is rapidly rising worldwide, paralleling the epidemic increase 
in obesity.  Because of its high content of calcium, magnesium, vitamin D, and whey 
proteins, which could reduce insulin resistance, dairy products could be hypothesized to 
protect against T2D (Rice et al., 2011). The meta-analysis of Aune et al. (2013) evaluated 
the association between intake of dairy products and the risk of T2D from prospective 
cohort and nested case-control studies (n=17). Non-linear, inverse associations were 
found between the risk of T2D and intakes of dairy products, low-fat dairy, yogurt, and 
cheese, the latter being the highest in fat content. The risk responses to dairy intake were 
dose-dependent, and flattened at higher intakes. Interestingly, high fat dairy did not alter 
the T2D risk in this study, although a meta-analysis focused specifically on butter 
consumption (Pimpin et al., 2016; 11 country-specific cohorts and 201,628 participants) 
reported butter intake was associated with a reduction of T2D risk. This discrepancy may 
suggest that the effects of dairy fat may be food-specific (e.g. cheese different from 
butter), a concept that merits further investigation. Other recent meta-analyses add 
support to the protective effects of dairy consumption against T2D (Forouhi et al., 2014; 
de Souza et al., 2015; Yakoob et al., 2016). For example, the prospective associations 
between circulating fatty acids in phospholipids and T2D were reported in individuals from 
the EPIC-InterAct case-cohort study (17,928 T2D subjects and 16,835 participants in a 
 C 
1.0 1.0 1.0 
random subcohort; Forouhi et al., 2014). By design, this study combines the temporal 
sequence and power advantages of a larger prospective cohort, with the measurement 
efficiency of a case-control. Forouhi et al., 2014 reported reduced hazard ratios for 
incident T2D in association with the odd chain SFA 15:0 and 17:0, both of which are 
mostly derived from dairy products. Similarly, using two prospective cohorts with 3333 
adults aged 30 to 75 years, free of T2D at baseline, and followed during 15 years, Yakoob 
et al. (2016) found that individuals at the highest quartile of plasma 15:0, 17:0, and t-
16:1n-7 had reduced risk of incident diabetes mellitus (-44%, -43%, and -53%, 
respectively; Figure 2). This last finding is of particular interest given that other studies 
have showed that circulating trans-palmitoleic acid (t-16:1n-7) is associated with lower 
insulin resistance, atherogenic dyslipidemia, and incident diabetes (Mozaffarian et al., 
2010; de Souza et al., 2015). Importantly, whole-fat dairy consumption is most associated 
with elevated plasma concentrations of trans-palmitoleic acid (Mozaffarian et al., 2010). 
Whether the apparently beneficial effects of dairy on T2D risk are mediated by trans-
palmitoleic acid or other components of dairy, remains to be experimentally elucidated; 
regardless, this possibility constitutes an exciting new direction for fatty acid research. 
 
 
 
 
 
 
 
 
 
Figure 2. Circulating biomarkers of dairy fat intake and risk of incident diabetes mellitus 
in two large prospective cohorts using 3,333 adults in a 15-year follow-up 
(Adapted from Yakoob et al., 2016). Solid-black and dashed-red lines represent 
hazard ratios (HR) and their 95% confidence intervals, respectively, for plasma 
A)15:0, B)17:0, and C) t-16:1n-7.   
 
Metabolic Syndrome  
 
Metabolic syndrome (MetS) consists of a cluster of cardiovascular risk factors that 
include central obesity, hyperglycemia, hypertriglyceridemia, low HDL-C, and 
hypertension (Alberti et al., 2009). Moreover, MetS is closely associated with CVD risk, 
T2D, all-cause mortality and cancer (Saely et al., 2007; Wu et al., 2010; Esposito et al., 
2012). Despite the recognition of the potential of dairy products to prevent or alleviate 
CVD, T2D and blood pressure in adults (e.g., 2010 Dietary guidelines for Americans; 
USDA/USDHHS, 2010), data on the relationship between dairy consumption and MetS is 
very limited. Chen et al. (2015) evaluated currently available data from cross-
sectional/case control studies (n=16) and prospective cohort studies (n=7) in two different 
meta-analyses. Comparing high vs. low dairy products intake, both meta-analyses 
showed a reduction in MetS risk with high dairy consumption, an observation that was 
maintained when the studies were evaluated by stratified subgroups (e.g. geographic 
region, sex, type of dairy, and follow-up duration). Finally, a dose response analysis of 
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 prospective cohorts in the same study showed an inverse relation between MetS risk and 
dairy consumption (Chen et al., 2015). Interestingly, the reduction in risk became evident 
when dairy intake was higher than 2 servings per day, and behaved linearly thereafter. 
This would suggest a minimum amount of dairy may be needed to impact MetS risk in a 
beneficial manner.     
  
CVD Risk and CVD Mortality 
 
As discussed previously, the relationship between SFA consumption and CVD is 
not straightforward, and it was historically derived from the diet-heart hypothesis, with two 
important premises: 1) SFA can influence circulating cholesterol (i.e., increase LDL-C), 
and 2) cholesterol is a risk factor for CVD. The resulting assumption was, therefore, that 
SFA consumption can cause CVD. Given the disconnect between SFA consumption and 
the anticipated clinical CVD outcomes (e.g., Siri Tarino et al., 2010; Chowdhury et al., 
2014), the strength of the diet-heart hypothesis has been questioned. Considering that 
dairy products may have protective effects against obesity, T2D, and metabolic 
syndrome, it is important to elucidate whether this may also be true for CVD, which 
remains a major cause of death in the United States (Mozaffarian et al., 2015). When 
looking at the effects of dairy consumption on CVD risk factors, the most salient finding 
is that, contrary to expectations, reducing SFA intake from dairy increases CVD risk, as 
determined by commonly used markers (Lefevre et al., 2005; Table 1). This sobering 
observation seems to receive further support from other studies that report significant 
associations between milk-derived fatty acids and a more favorable LDL particle size 
distribution (i.e., reduction in small dense LDL particles; Sjogren et al., 2004). 
Furthermore, some SFA found in milk fat, such as lauric acid, are actually associated with 
a reduction of CVD risk (Micha and Mozaffarian., 2010). Importantly, these pieces of 
evidence align with the solid, general observation, that SFA are neutral or even beneficial 
in terms of CVD risk. 
 
Focusing on evidence from prospective data, Elwood et al., (2008) conducted a 
meta-analysis of 15 prospective cohort studies reporting the association between milk 
and dairy consumption and the incidence of vascular diseases in the UK. The relative risk 
(RR) of stroke and/or heart disease was significantly reduced in subjects with high milk 
or dairy consumption (RR =0.84 and 0.79, respectively), compared with the risk in those 
with low consumption. These findings highlight once more, the disconnect between the 
hypothesized effects of SFA-containing foods like dairy, and the actual clinical outcomes 
of interest. Similarly, a systematic review of the available literature indicates that most 
studies do not support the expected effects of dairy fat on CVD, and that discrepancies 
may be associated to country-specific effects (Kratz et al., 2012). Specifically, the Nurses’ 
Health study (from the US) found a consistent positive association between dairy fat 
intake and CVD, while 11 other studies across Europe, Costa Rica, and Australia, showed 
either no association or an inverse relationship between CVD and dairy fat intake. Only 
one of these 11 studies reported a discrepancy, as it found an inverse association in men, 
but a positive one in women (Kratz et al., 2012). The authors suggested that residual 
confounding from lifestyle factors associated with dairy intake, as well as differences in 
food sources of dairy fat, may help explain the discrepancy between US and non-US data. 
 Relevant to this point, the recently published results from the Prospective Urban Rural 
Epidemiology (PURE) study evaluated the effects of dairy consumption on death and 
major CVD events across 21 countries and 5 continents in an 9-year follow-up (Dehghan 
et al., 2018). Dietary intakes of dairy products for 136,384 individuals were recorded using 
country-specific validated food frequency questionnaires. Dairy foods evaluated included 
milk, yoghurt, and cheese, and these were grouped into whole-fat and low-fat dairy. Dairy 
intake above 2 servings per day reduced the risk of total mortality, CVD mortality, major 
CVD, and stroke, relative to no intake. Similarly, whole-fat dairy (> 2 servings per day) 
was inversely associated with total mortality and major CVD. Interestingly, the CVD 
response to whole-fat dairy appeared to be dose-responsive, as it increased 
progressively from <0.5 to 0.5-1, 1-2, and >2 servings per day. Cheese consumption (>1 
serving per day) was associated with reduced mortality and major CVD, while the effect 
of butter was neutral (i.e., no increase in risk). The PURE study suggests that dairy intake, 
especially whole-fat dairy, might be beneficial for preventing deaths and major 
cardiovascular diseases. Moreover, there seems to be no disadvantage associated with 
the consumption of full-fat dairy, compared with the low-fat counterparts. The authors 
conclude that consumption of dairy products should not be discouraged and perhaps 
should even be encouraged, particularly in low-income and middle-income countries 
where dairy consumption is low. 
 
The mechanistic modes of action by which milk and dairy products may be 
protective against CVD and other health outcomes is likely complex and still requires 
investigation. It is important to bear in mind that bovine milk contains an outstanding 
number of bioactive components (Park, 2009), which may interact additively, 
synergistically, or antagonistically. The heavy focus on single nutrients during the past 
decades (e.g., saturated fats should be avoided) has proven narrow in scope and of 
limited ability to predict health outcomes. As proposed by others (Mozaffarian, 2014), 
food-based guidelines that reduce confusion for consumers and are based on prospective 
evidence for effects on clinical endpoints are needed.  
 
CONCLUSION    
 
We may be in the midst of a paradigm shift in human nutrition. The revaluation of the 
validity of classic literature and the emerging plethora of evidence over the past decade, 
strongly contradict the long-held idea that dietary saturated fats cause adverse effects on 
health. Moreover, as shown in this review, current evidence indicates that dairy products, 
including full-fat dairy, may exert protective effects on metabolic health, reducing the 
incidence of obesity, T2D, MetS, CVD, and mortality. In light of this evidence, a general 
call to revise the guidelines on dairy consumption seems strongly justified and necessary, 
particularly as dairy products may help combat the spread of chronic diseases. Moreover, 
the historic focus on individual nutrients (e.g., fat, calories) has proven limited in terms of 
predicting clinical outcomes. In this sense, a whole-food approach to studying the effects 
of the ensemble of nutrients contained in dairy foods on human health outcomes seems 
warranted. Lastly, policy changes should be guided by a more nuanced interpretation of 
observational studies, and reflect the value of repeatable, randomized controlled studies, 
as the latter may provide insights on causality and the role of dairy on public health.  
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